TX-004HR Provides Robust Efficacy for Symptomatic Postmenopausal Vulvar and Vaginal Atrophy (VVA) while Providing Negligible to Very Low Systemic Absorption of Estradiol: Results of Clinical Phase 2 and 3 Trials

TX-004HR Provides Robust Efficacy for Symptomatic Postmenopausal Vulvar and Vaginal Atrophy (VVA) while Providing Negligible to Very Low Systemic Absorption of Estradiol: Results of Clinical Phase 2 and 3 Trials Meeting Abstract

authors

Archer, David F.

publication date

December 1, 2016

webpage

Web of Science

published in

MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY Journal

start page

1374

end page

1375

volume

23

issue

12